FNDC5 and sarcopenia: Accordingly, irisin is considered a promising biomarker of sarcopenia and frailty [128,129] since its levels are markedly reduced during aging, and as demonstrated by Chang et al. [128], low circulating irisin levels are a sensitive marker for muscle weakness and atrophy.